Recent Research on Adenovirus-Vectored Vaccines
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Attenuated/Inactivated/Live and Vectored Vaccines".
Deadline for manuscript submissions: 31 May 2026 | Viewed by 14
Special Issue Editors
Interests: adenovirus-vectored vaccine; gene-based vaccines; gene therapy; oncolytic viruses; virology; immunology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
As we move forward from the COVID-19 pandemic and focus on both emerging and previously recognized pathogens, we invite you to contribute to a Special Issue on ‘Recent Research on Adenovirus-Vectored Vaccines’. The pandemic has provided valuable insights into the development of vaccines against coronaviruses and other viruses. Replication-deficient viral vaccines have been shown to effectively induce neutralizing antibodies and cellular immune responses, thereby providing adequate immune protection. This Special Issue is an opportunity to address these experiences. We are interested in studies that examine the persistence of immune responses after vaccination against SARS-CoV-2, other pathogens, or cancers, especially in comparison to other vaccine platforms. We also welcome comparisons among different types of adenovirus vaccines, including replicating, single-cycle, replication-defective, and helper-dependent variants and different serotypes.
We look forward to receiving your contributions.
Dr. Michael A. Barry
Dr. Vijay S. Reddy
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- adenovirus
- replication competent
- single cycle
- replication defective
- serotypes
- targeting
- structure
- cryo-EM
- vaccines
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
